<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
<journal-id journal-id-type="publisher-id">hmg</journal-id>
<journal-id journal-id-type="hwp">hmg</journal-id>
<journal-title-group>
<journal-title>Human Molecular Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0964-6906</issn>
<issn pub-type="epub">1460-2083</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26908602</article-id>
<article-id pub-id-type="pmc">4986326</article-id>
<article-id pub-id-type="doi">10.1093/hmg/ddw038</article-id>
<article-id pub-id-type="publisher-id">ddw038</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Acute and crucial requirement for MeCP2 function upon transition from early to late adult stages of brain maturation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Du</surname>
<given-names>Fang</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="author-notes" rid="AN1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nguyen</surname>
<given-names>Minh Vu Chuong</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="author-notes" rid="AN2">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karten</surname>
<given-names>Ariel</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Felice</surname>
<given-names>Christy A.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mandel</surname>
<given-names>Gail</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ballas</surname>
<given-names>Nurit</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="af1"><sup>1</sup>Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794, USA and</aff>
<aff id="af2"><sup>2</sup>Vollum Institute, Howard Hughes Medical Institute, Oregon Health and Science University, Portland, OR 97239, USA</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">*To whom correspondence should be addressed. Tel: +1 631 632 1572; Fax: +1 631 632 8575; Email: <email>nurit.ballas@stonybrook.edu</email></corresp>
<fn fn-type="con" id="AN1">
<p><sup>†</sup>Present address: Department of Pharmacology and Toxicology, Kansas University School of Pharmacology, Kansas.</p>
</fn>
<fn fn-type="con" id="AN2">
<label>‡</label>
<p>Present address: GREPI-UGA EA7408, Université Grenoble Alpes, Grenoble, France.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>01</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>25</volume>
<issue>9</issue>
<fpage>1690</fpage>
<lpage>1702</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="ddw038.pdf"></self-uri>
<abstract>
<p>Germline mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2), underlie most cases of Rett syndrome (RTT), an autism spectrum disorder affecting approximately one in 10 000 female live births. The disease is characterized in affected girls by a latent appearance of symptoms between 12 and 18 months of age while boys usually die before the age of two. The nature of the latency is not known, but RTT-like phenotypes are recapitulated in mouse models, even when MeCP2 is removed at different postnatal stages, including juvenile and adolescent stages. Unexpectedly, here, we show that within a very brief developmental window, between 10 (adolescent) and 15 (adult) weeks after birth, symptom initiation and progression upon removal of MeCP2 in male mice transitions from 3 to 4 months to only several days, followed by lethality. We further show that this accelerated development of RTT phenotype and lethality occur at the transition to adult stage (15 weeks of age) and persists thereafter. Importantly, within this abbreviated time frame of days, the brain acquires dramatic anatomical, cellular and molecular abnormalities, typical of classical RTT. This study reveals a new postnatal developmental stage, which coincides with full-brain maturation, where the structure/function of the brain is extremely sensitive to levels of MeCP2 and loss of MeCP2 leads to precipitous collapse of the neuronal networks and incompatibility with life within days.</p>
</abstract>
<funding-group>
<award-group id="funding-1">
<funding-source>National Institute of Health</funding-source>
<award-id>R01HD056503</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>Investigator of the Howard Hughes Medical Institute</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="13"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>